Longeveron Inc. stock is up 17.62% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.
Longeveron Inc. develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product. It is conducting Phase 1 and 2 clinical trials in various indications.